Organometallic Ligands

eIF4A3-IN-2 is a small molecule inhibitor targeting eIF4A3, which is a DEAD-box RNA helicase. This compound is synthesized from a chemical library designed to modulate RNA-binding proteins. Its mode of action involves binding to eIF4A3 to inhibit its helicase activity, thereby disrupting the process of nonsense-mediated mRNA decay and pre-mRNA splicing. This specific inhibition is particularly valuable for exploring the regulation of gene expression at the post-transcriptional level. In scientific research, eIF4A3-IN-2 is employed to study the intricate mechanisms of RNA processing and the role of RNA helicases in cellular biology. Its application helps in elucidating the pathways involved in mRNA surveillance and the dynamic regulation of splicing, which can have implications in cancer research and the development of therapeutic strategies targeting dysregulated RNA processing in various diseases. Researchers utilize this inhibitor to better understand the molecular underpinnings of splicing-related pathologies, providing insights into potential interventions for conditions where aberrant RNA metabolism is a hallmark.

Rebamipide is a gastroprotective agent that is used to treat various gastrointestinal disorders such as gastric ulcers and GERD. This drug’s mechanism of action is not fully understood however, it is thought to exert its effects by promoting the secretion of protective mucus in the stomach and intestine, which helps to create a barrier against stomach acid and other irritants. Additionally, it has antioxidant and anti-inflammatory properties that can help reduce tissue damage. Rebamipide is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

CYP17 lyase inhibitor; androgen receptor antagonist

Jionoside A1 is a triterpenoid saponin, which is a naturally occurring compound principally derived from the plant species Cyclocarya paliurus. These saponins are secondary metabolites that exhibit a diverse range of biological activities. The source of Jionoside A1, Cyclocarya paliurus, is known for its medicinal properties and is traditionally used in various herbal formulations. The mode of action of Jionoside A1 involves its ability to disrupt cellular membranes due to its amphipathic nature. This action not only facilitates its antibacterial properties by compromising the integrity of bacterial cell walls but also contributes to its antioxidant activity through neutralization of free radicals. Jionoside A1 finds potential applications in the pharmaceutical and nutraceutical industries due to its antibacterial and antioxidant effects. In pharmaceutical research, it is studied for its ability to combat bacterial infections and its potential role in mitigating oxidative stress-related diseases. In addition, its bioactive properties open avenues for exploration in the development of functional foods and dietary supplements aiming to enhance health and provide therapeutic benefits.

Antagonist of nicotinic acetylcholine receptors; nondepolarising muscle relaxant

FK 102 CO(III) PF6 is a cobalt(III) complex salt, which is a coordination compound utilized extensively in organometallic chemistry and catalysis. Derived from cobalt, a transition metal known for its diverse oxidation states and coordination abilities, this compound is synthesized through the combination of cobalt with specific ligands, resulting in a hexafluorophosphate salt. The mode of action of this complex involves its ability to facilitate electron transfer processes, making it an excellent catalyst for various organic reactions. In research applications, FK 102 CO(III) PF6 is employed in the study of reaction mechanisms and in the development of new synthetic pathways. Its unique properties make it suitable for applications in fields such as polymerization, oxidation-reduction reactions, and cross-coupling reactions. Scientists benefit from its stability and reactivity, which are pivotal for understanding and optimizing catalytic processes. By offering a reliable means to explore complex chemical transformations, FK 102 CO(III) PF6 significantly contributes to advancements in material science and synthetic chemistry.

Please enquire for more information about VU0453379 including the price, delivery time and more detailed product information at the technical inquiry form on this page

C16(Plasm) LPC is a lysophosphatidylcholine, a type of lysophospholipid derived predominantly from plasma membrane phospholipids. It originates from the enzymatic action of phospholipase A2, which cleaves the fatty acid chain, typically at the sn-2 position. This leaves behind the lysophospholipid with a single acyl chain. LPC serves as a bioactive signaling molecule, facilitating cellular communication by acting on G protein-coupled receptors and influencing immune cell activity. It can act as an emulsifying agent in biochemical reactions and influence lipid metabolism. LPC is also involved in the regulation of inflammatory responses and is implicated in pathophysiological conditions such as atherosclerosis and metabolic syndrome. Its presence and abundance can serve as biomarkers for various diseases, and it plays roles in the modulation of endothelial cell function, smooth muscle activity, and oxidative stress response. In research applications, C16(Plasm) LPC is used to study cell signaling pathways, particularly in the context of inflammation and metabolic diseases. The product serves as a valuable tool for scientists investigating lipid-mediated signaling mechanisms and their broader physiological implications.

ATP-Red 1 is a fluorescent probe, which is a synthetic molecule that allows for the visualization and quantification of adenosine triphosphate (ATP) within live cells. This product is derived from benzothiazole, a heterocyclic compound, and it exploits the unique properties of this structure to detect ATP with high specificity. The mode of action of ATP-Red 1 involves a fluorescence enhancement mechanism, where its binding to ATP results in a significant increase in fluorescence intensity. This enables the direct monitoring of ATP dynamics in real-time. The primary use of ATP-Red 1 is in the measurement of cellular energy states, providing insights into metabolic processes and cellular health. It is particularly valuable in studies of mitochondrial function and bioenergetics, where ATP plays a critical role. Researchers can utilize this probe in live-cell imaging experiments to assess changes in ATP concentrations, thereby gaining a deeper understanding of cellular metabolism under various physiological conditions. This application is pivotal in fields such as pharmacology, cancer research, and neurology, where alterations in energy metabolism are often implicated.

an ADC drug-linker conjugate composed of an DX-8951 derivative (Exatecan) and a maleimide-GGFG peptide linker.

Please enquire for more information about GB1107 including the price, delivery time and more detailed product information at the technical inquiry form on this page

Antagonist of platelet activating factor

Miransertib (ARQ 092) HCl is a selective inhibitor, which is a synthetic small molecule specifically targeting the AKT pathway. It is sourced through specialized chemical synthesis designed to interfere with key signaling pathways implicated in the proliferation and survival of cancer cells. The mode of action involves the inhibition of the serine/threonine kinase AKT, an integral part of the PI3K/AKT/mTOR signaling pathway that is frequently dysregulated in various cancers. Miransertib's ability to inhibit AKT disrupts aberrant signaling cascades, leading to the suppression of cancer cell growth and induction of apoptosis. Its primary uses and applications are in the therapeutic investigation of disorders such as Proteus syndrome, PIK3CA-related overgrowth spectrum (PROS), and situations where AKT pathway activation contributes to oncogenesis. Current research includes clinical trials focusing on its efficacy and safety profile to better understand its potential as a targeted cancer therapy.

DPP-4 enzyme inhibitor; anti-diabetic

Dapagliflozin is a sodium-glucose cotransporter subtype 2 (SGLT2) inhibitor that can be used in the treatment of diabetes mellitus type 2. It inhibits glucose reabsorption in the proximal tubule of the nephron and results in glycosuria, which helps to improve glycaemic control. Also, Dapagliflozin is used to lower the risk of sustained eGFR decline, end-stage renal disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease who are at risk of progression. Dapagliflozin is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Ondansetron is a serotonin 5-HT3 receptor antagonist that is used to prevent vomiting and nausea in patients undergoing chemotherapy. This drug blocks the initiation of the vomiting reflex. Ondansetron HCl dihydrate is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Inhibitor of S-adenosylhomocysteine hydrolase that disrupts histone methylation by EZH2. Anti-proliferative in some breast cancer and invasive prostate cancer cell lines. One of four key molecules required for inducing chemical reprogramming of somatic cells into induced pluripotent stem cells (iPSC).

eV1-2 is a selective εPKC inhibitor peptide which interferes with protein-protein interactions between the ϵPKC isozyme and its anchoring protein (ϵRACK). ϵPKC and ϵRACK regulate the contraction rate of heart muscle cells and provide protection from ischemia induced cell death. ϵV1-2 is derived from the C2 domain of ϵPKC, a region important for protein-protein interactions and thus acts as a competitive inhibitor of these interactions. The C2 region is well conserved between species, but different enough from other PKC isozymes to allow for targeted inhibition (ϵV1-2 is 88% identical between sea slugs and rat ϵPKC, yet only 36% identical between rat ϵPKC and rat θ'PKC). This peptide contains a C-terminal cysteine residue for conjugation to a carrier protein.

NSC 135130 is a synthetic compound that serves as an antioxidant and anti-inflammatory agent. It is derived through chemical synthesis, a process involving the combination of various elements and compounds to produce a novel substance with specific desired properties. The mode of action of NSC 135130 primarily involves the scavenging of free radicals and modulation of inflammatory pathways, thus helping to mitigate oxidative stress and inflammation at the cellular level. This compound is under investigation for its potential therapeutic applications in various inflammatory and oxidative stress-related conditions. Its efficacy in minimizing cellular damage makes it a candidate for further research in diseases where oxidative damage and inflammation play a critical role, such as cardiovascular diseases, neurodegenerative disorders, and certain cancers. Ongoing studies aim to elucidate its pharmacokinetics, bioavailability, and long-term effects in biological systems to better understand its potential clinical value.

Trk-in-3 is an inhibitor specifically targeting tyrosine kinase receptors, derived from a combination of synthesized natural compounds. This inhibitor functions by selectively binding to the ATP-binding site of Trk receptors, thus disrupting downstream signaling pathways that are crucial for cellular proliferation and survival. Trk-in-3's mode of action involves the interruption of neurotrophic signaling, which is fundamentally important in the regulation of neuronal growth, differentiation, and apoptosis. By blocking these signaling pathways, Trk-in-3 can effectively modulate neurotrophic support in various cellular contexts. The applications of Trk-in-3 are expansive, making it a potent tool in research focused on neurodegenerative disorders, cancer, and other diseases characterized by aberrant signaling pathways. In scientific investigations, Trk-in-3 is utilized to elucidate the roles of Trk signaling in disease pathogenesis and to explore therapeutic interventions targeting these pathways. Its specificity and efficacy in inhibiting Trk activation positions Trk-in-3 as a critical compound in both preclinical studies and experimental therapeutic strategies.